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TBI. CD3+, CD4+ and CD8+ doses were analyzed above vs.
below the median dose. TNC dose was analyzed < vs  8 x
108 cells/kg; CD34+ was analyzed< vs 4 x 106 cells/kg. The
median (range) follow-up was 3.2 (<0.1-11) years. Time to
neutrophil engraftment was shorter in patients with  4 x
106 CD34+ cells/kg (14 vs 15 days, P¼.051), but was only
signiﬁcant in TBI-based conditioning (P¼.007 TBI, P¼NS no
TBI). Time to platelet engraftment was also signiﬁcantly
shorter in patients with  4 x 106 CD34+ cells/kg (17 vs 21
days, P¼.004); but was only signiﬁcant in the MA+TBI
(P¼.001) and RIC-noTBI (P¼.023) subgroups. CD34+ dose was
not associated with overall survival (OS) (Figure, Table),
progression free survival (PFS, Table) or development of
acute GVHD (grade II-IV or III-IV), either in the entire cohort
or in any conditioning subgroups. CD3+, CD4+ and CD8+ cell
doses were not associated with any outcomes in the entire
cohort or in any conditioning subgroups. OS and PFS were
both improved for patients receiving either a MA or RICTBI-based regimen and a TNC 8 x 108 cells/kg (Figure,
Table). The TNC dose did not correlate with CD34+ dose and
is therefore an independent predictor of outcomes. Our study
suggests that understanding blood graft cell composition is
needed, and that conditioning regimen may inﬂuence the
desired cell dose. Further study may allow us to identify
which cell population in the TNC is associated with out-
comes.13
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Purpose: The effect of sequencing Cy and myeloablative
doses of TBI in the conditioning regimen on HCT outcomes in
humans is unknown. In rodent experiments, however, it has
been suggested that TBI followed by Cy (TBICy) is superior in
reducing lung toxicity, but also results in an increased inci-
dence of bone marrow damage. In contrast, Cy followed by
TBI (CyTBI) has been reported to be associated with an
improved anti-leukemic effect with increased risk of hepatic
sinusoidal obstructive syndrome (SOS).
Study Design: The sequence of Cy and TBI (1200-1500cGY)
was evaluated in 1,769 recipients of related or unrelated
donor HCT, younger than 60 years with acute leukemia (AML
n¼945, ALL¼ 824) who were reported to the Center for In-
ternational Blood andMarrow Transplant Research (CIBMTR)
from 2003 to 2010.Patient Characteristics Cy TBI TBI Cy
Median Age 35 34
Performance status> 90 69% 74%
AML 52% 55%
CR1 64% 64%
Ph+ ALL 25% 25%
BM stem cell source 34% 37%
HLA sibling 35% 34%
ATG 11% 13%
TBI dose 1200-1300 cGy 61% 63%
Tacrolimus/Methotrexate 43% 45%
Figure 1.
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received TBICy. The two cohortswere comparable for patient-,
disease- and transplant-related characteristics (Table). The
sequence of TBI did not signiﬁcantly affect TRM (24% vs. 23%
@3y, p¼0.67; relative risk [RR] 1.01, p¼0.91), leukemia relapse
(27% vs. 29% @3y, p¼0.34; RR 0.89, p¼0.18), leukemia-free
survival (48% vs. 49% @3y, p¼0.27; RR 0.93, p¼0.29), chronic
graft vs. host disease (GVHD) (45%vs. 47%@1y, p¼0.39; RR0.9,
p¼ 0.11) or overall survival (53% vs. 52%@3y, p¼0.62; RR 0.96,
p¼0.57) for CyTBI and TBICy respectively. Corresponding cu-
mulative incidences of SOS were 4% and 6% @100days
(p¼0.08).While grades II-IV acute GVHD@100 dayswere 39%
vs. 45% (p¼0.01), multivariate analysis of grades II-IV acute
GVHD resulted in a RR of 0.87 (95% CI 0.75-1.00, p¼0.052).
Grades III-IV acute GVHD @100 days were 16% vs. 15%
(p¼0.62). Interaction between disease and conditioning
sequence did not show any differential effect for AML or ALL.
Conclusions: This study demonstrates that the sequence of
Cy and TBI does not impact transplant outcomes and com-
plications in patients with acute leukemia undergoing mye-
loablative transplantation. Furthermore, the results suggest
that Grades II-IV but not III-IV acute GVHD are possibly lower
with CyTBI sequence, although further evaluation is
warranted to conﬁrm this ﬁnding.14
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Aim: The composition and frequency of HLA alleles and
haplotypes vary by race/ethnic populations. Consequently, it
is thought that patients (pts) in need of an allogeneic stem
cell transplant are most likely to identify a suitably HLA
matched cell source within their own racial/ethnic group.
This study evaluated the degree of race/ethnic matching for
U.S. pts who received a transplant facilitated by Be TheMatch
Registry (BTMR).
Method: 11,870 transplants for U.S pts using a U.S donor or
cord blood unit (CBU) in BTMR database from January 2008Figure 2to October 2013 were evaluated. Pt cohort was restricted to
thosewho self identiﬁed their race/ethnicity under the broad
classiﬁcation of Black (AFA), Asian/Paciﬁc Islander (API),
White (CAU), and Hispanic (HIS). Cell source self identiﬁed
race/ethnicity were clustered into the broad race group of
AFA, API, CAU, and HIS. If the broad race/ethnicity of the pt
and source were identical the case was considered a match.
When more than one race and/or ethnicity was reported in a
pt/source they were considered race/ethnic matched if at
least one same broad race/ethnic group was reported for
both. 9243(78%) of the pts were self described as CAU with
1108 AFA, 917 HIS, and 602 API contributing 9.3%, 7.7%, and
5.1%, respectively. Comparison of race matching along with
HLA matching at transplant was also evaluated. The HLA
match was assigned a match category of x of 10 for donors
and x of 6 (antigen level HLA-A,B, allele HLA-DRB1) for CBUs
utilizing the typing provided by the transplant center.
Results: Figure 1 shows the percent of race/ethnic matching
between the pt and transplanted cell source. Greater
than 90% of CAU and HIS pt populations transplanted with a
race/ethnic matched donor or CBU, contrasted with AFA and
API pts who transplanted with race/ethnic matched CBU
less than 60% of the time. AFA and API pts showed variation
between cell sources, transplanting less often with a race/
ethnic matched CBU than donor. Further analysis of the level
of HLA match in relation to race match shows increased HLA
mismatches when the source was race/ethnic mismatched
(Figure 2). In all populations, when the source is race/ethnic.
